scholarly journals Linking the Diagnostic Imaging Dataset (DID) to Hospital Episode Statistics (HES) – improving and understanding the diagnosis of lung cancer

2017 ◽  
Vol 1 (1) ◽  
Author(s):  
David Kennedy ◽  
Abigail Bentley ◽  
Erika Denton ◽  
Ella Ohuma ◽  
Nick Ormison-Smith ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Diagnostic Imaging ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Emergency Admission ◽  
Hospital Episode Statistics ◽  
X Rays ◽  
Hospital Episode ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

ABSTRACT ObjectivesTo link the Diagnostic Imaging Dataset (DID) to Hospital Episode Statistics (HES) to explore the association between patient imaging and hospital based care and outcomes for cancer patients in English NHS hospitals. This is the first time this linkage has taken place. The analysis also aims to look at how each patient first presented in HES (A&E, emergency admission, elective care, regular attendance), when and by what route relevant tests were requested and geographic variation in access to imaging ApproachPatient imaging records from the DID were linked to HES databases containing details of all inpatient, outpatient and A&E admissions at NHS hospitals in England in 2012/13 and 2013/14. Match rank criteria were developed to ensure that patients in HES were accurately linked to patients in DID by NHS number, date of birth and other unique identifiers. We used HES to identify patients with a lung cancer diagnosis and investigate their use of imaging and the temporal nature of tests to evaluate whether patients were following recommended pathways (e.g. having chest x-rays followed by CT scans before their lung cancer diagnosis) and the time between these events. Lung cancer patients were identified by developing an algorithm to search through diagnostic fields for clinical codes within HES databases. Where there was a lung cancer code the record was flagged and subsequently extracted. ResultsThe combined HES and DID datasets consisted of more than 340 million records. Within this large dataset we identified 49,888 patients with a lung cancer code in one of their HES diagnosis fields to a DID diagnostic image record for inpatient records alone. A high proportion (97%) of records were matched in one of the top 3 rank levels, suggesting the linkage was successful. The results illustrate the relationship between the imaging referral pathway and hospital episodes (e.g. surgical resection, emergency presentation). ConclusionInvestigating how people engage with imaging services and hospital care will increase our understanding of the pathways associated with lung cancer diagnosis. The results from this analysis will contribute new knowledge about how lung cancer patients interact with hospitals and imaging services.

scholarly journals Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11528
Author(s):  
Wen-Jun Zhu ◽  
Bo-Jiang Chen ◽  
Ying-Ying Zhu ◽  
Ling Sun ◽  
Yu-Chen Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Roc Curve ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

scholarly journals Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules

2020 ◽  
Vol 146 (12) ◽  
pp. 3349-3357
Author(s):  
Yunli Huo ◽  
Zijian Guo ◽  
Xuehui Gao ◽  
Zhongjuan Liu ◽  
Ruili Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Predictive Value ◽  
Positive Test ◽  
Test Results ◽  
Newly Diagnosed ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Abstract Purpose Increasing lung cancer incidence in China with a high death rate due to late diagnosis highlights the need for biomarkers, such as panels of autoantibodies (AAbs), for prediction and early lung cancer diagnosis. We conducted a study to further evaluate the clinical performance of an AAb diagnostic kit. Methods Using enzyme-linked immunosorbent assay, levels of seven AAbs in serum samples from 121 patients with newly diagnosed lung cancer, 84 controls (34 healthy individuals and 50 patients with benign lung disease), and 100 indeterminate solid nodules, were measured. Participants were followed up until 6 months after a positive test result to confirm lung cancer diagnosis. Results The seven AAb concentration was significantly higher in lung cancer patients than in controls (P < 0.05). The seven AAb sensitivity and specificity for newly diagnosed lung cancer were 45.5% and 85.3%, respectively, while the seven AAb combined area under the curve (in lung cancer patients versus controls) was 0.660. Of the 28 patients with solid nodules with positive test results, 8 and 3 were diagnosed with lung cancer and benign lung disease, respectively, during follow-up. The positive predictive value of the experiment was 72.7%. Conclusion Positive AAb test results were associated with a high risk of lung cancer. The seven-AAb panel also had a high predictive value for detecting lung cancer in patients with solid nodules. Our seven lung cancer autoantibody types can provide an important early warning sign in the clinical setting.

Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis

2021 ◽  
Vol 18 (2) ◽  
pp. 129-139
Author(s):  
Sai Ren ◽  
Xiaodong Ren ◽  
Haiqin Guo ◽  
Lan Liang ◽  
Kun Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Characteristic Curve ◽  
Healthy Controls ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Free Dna ◽  
Pcr Targeting

Aim: To explore the role of urine cell-free DNA (ucfDNA) concentration and integrity indexes as potential biomarkers for lung cancer diagnosis. Materials & methods: Quantitative real-time PCR targeting Arthrobacter luteus ( ALU) repeats at three size fragments ( ALU-60, 115 and 247 bp) was performed in 55 lung cancer patients and 35 healthy individuals. Results: ucfDNA concentration and integrity indexes were significantly higher in lung cancer patients than in healthy controls. The area under the receiver operating characteristic curve for differentiating patients with stage I/II from healthy controls by ALU fragments concentration were 0.856, 0.909 and 0.932, respectively. In addition, the ucfDNA integrity indexes in patients with lymph node metastasis were significantly higher than in patients with non-metastatic. Conclusion: ucfDNA concentration and integrity indexes could serve as promising biomarkers for lung cancer diagnosis.

scholarly journals Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Shinechimeg Dima ◽  
Kun-Huang Chen ◽  
Kung-Jeng Wang ◽  
Kung-Min Wang ◽  
Nai-Chia Teng
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Physician Visits ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Kaplan Meier ◽  
Diagnosis Of Lung Cancer

The effect of comorbidity on lung cancer patients’ survival has been widely reported. The aim of this study was to investigate the effects of comorbidity on the establishment of the diagnosis of lung cancer and survival in lung cancer patients in Taiwan by using a nationwide population-based study design. This study collected various comorbidity patients and analyzed data regarding the lung cancer diagnosis and survival during a 16-year follow-up period (1995–2010). In total, 101,776 lung cancer patients were included, comprising 44,770 with and 57,006 without comorbidity. The Kaplan–Meier analyses were used to compare overall survival between lung cancer patients with and without comorbidity. In our cohort, chronic bronchitis patients who developed lung cancer had the lowest overall survival in one (45%), five (28.6%), and ten years (26.2%) since lung cancer diagnosis. Among lung cancer patients with nonpulmonary comorbidities, patients with hypertension had the lowest overall survival in one (47.9%), five (30.5%), and ten (28.2%) years since lung cancer diagnosis. In 2010, patients with and without comorbidity had 14.86 and 9.31 clinical visits, respectively. Lung cancer patients with preexisting comorbidity had higher frequency of physician visits. The presence of comorbid conditions was associated with early diagnosis of lung cancer.

Consistency of recording of chemotherapy cycles in the National Cancer Registration and Analysis Service Systemic Anti-Cancer Therapy database and the Hospital Episode Statistics Admitted Patient Care database

2020 ◽  
Vol 16 (3) ◽  
pp. 4455-4460
Author(s):  
Laura McDonald ◽  
Cormac Sammon ◽  
Robert Carroll ◽  
Akash Harish ◽  
Abhishek Shankar C ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Patient Care ◽  
Cancer Patients ◽  
Hospital Episode Statistics ◽  
Cancer Registration ◽  
Hospital Episode ◽  
Lung Cancer Patients ◽  
Anti Cancer ◽  
Care Database

Aim: We assessed the extent to which chemotherapy cycles recorded in Hospital Episode Statistics (HES) Admitted Patient Care (APC) were captured in National Cancer Registration & Analysis Service Systemic Anti-Cancer Therapy (SACT) for a cohort of lung cancer patients. Methods: All chemotherapy cycles recorded for linkage eligible lung cancer patients with a National Cancer Registration & Analysis Service diagnosis between 2012 and 2015 were identified in HES APC and SACT. Results: Among a population of 4070 lung cancer patients, 6076 chemotherapy cycles were observed in HES APC data. A total of 61% of cycles were recorded in SACT on the same day, 8% on a different day and 31% were not recorded in SACT. Conclusion: Our results suggest that SACT may not capture all chemotherapy cycles administered to a patient between 2012 and 2016; however, administrative changes mean data after this period may be more complete.

Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis

2014 ◽  
Vol 67 (8) ◽  
pp. 707-711 ◽  
Author(s):  
A Jasmijn Hubers ◽  
Paul Brinkman ◽  
Remco J Boksem ◽  
Robert J Rhodius ◽  
Birgit I Witte ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Breath Analysis ◽  
Exhaled Breath ◽  
Dna Hypermethylation ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Exhaled Breath Analysis ◽  
Validation Set

AimsThe aim of this study is to explore DNA hypermethylation analysis in sputum and exhaled breath analysis for their complementary, non-invasive diagnostic capacity in lung cancer.MethodsSputum samples and exhaled breath were prospectively collected from 20 lung cancer patients and 31 COPD controls (Set 1). An additional 18 lung cancer patients and 8 controls only collected exhaled breath as validation set (Set 2). DNA hypermethylation of biomarkers RASSF1A, cytoglobin, APC, FAM19A4, PHACTR3, 3OST2 and PRDM14 was considered, and breathprints from exhaled breath samples were created using an electronic nose (eNose).ResultsBoth DNA hypermethylation markers in sputum and eNose were independently able to distinguish lung cancer patients from controls. The combination of RASSF1A and 3OST2 hypermethylation had a sensitivity of 85% with a specificity of 74%. eNose had a sensitivity of 80% with a specificity of 48%. Sensitivity for lung cancer diagnosis increased to 100%, when RASSF1A hypermethylation was combined with eNose, with specificity of 42%. Both methods showed to be complementary to each other (p≤0.011). eNose results were reproducible in Set 2.ConclusionsWhen used in concert, RASSF1A hypermethylation in sputum and exhaled breath analysis are complementary for lung cancer diagnosis, with 100% sensitivity in this series. This finding should be further validated.

scholarly journals Distributions of Usage and the Costs of Conventional Medicine and Traditional Chinese Medicine for Lung Cancer Patients in Taiwan

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Yueh-Hsiang Liao ◽  
Jaung-Geng Lin ◽  
Cheng-Chieh Lin ◽  
Tsai-Chung Li
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Conventional Medicine ◽  
Outpatient Services ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Before And After ◽  
Utilization Patterns ◽  
One Year

Background. This study aims to analyze the utilization patterns of patients with lung cancer stratified by surgery status.Methods. A retrospective cohort study was conducted from 1996 to 2010 by using the Longitudinal Health Insurance Database 2005.Results. Among the 7,677 lung cancer patients, 230 (31.17%) and 1,826 (26.32%) who have and have not undergone surgery have used TCM outpatient services, respectively. For lung cancer patients who have not undergone surgery, patients who are aged 70 years and older, males, occupational members, and farmers and fishermen are less likely to avail of TCM services. For lung cancer patients who have undergone surgery, the likelihood of TCM users is higher in residents who used TCM one year prior to lung cancer diagnosis and in patients with insurance amounts ranging from ≥NT$60,000. The total amount paid per visit for WM is higher than that for one year of TCM outpatient care before and after lung cancer diagnosis.Conclusion. The factors associated with TCM use varied according to surgery status. The costs of insurance covering TCM were consistently lower than those covering WM for lung cancer patients. These findings would be useful for health policy makers who are considering TCM and WM integration.

scholarly journals Cytological and histological diagnosis of lung cancer in Sardinia and Italy in the 1990s

2016 ◽  
Vol 67 (4) ◽  
Author(s):  
P. Pirina ◽  
M. Budroni ◽  
S. Esposito ◽  
S. Ostera ◽  
M.F. Polo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Cancer Registries ◽  
Histological Diagnosis ◽  
Cytological Diagnosis ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

Background. Up to 30-50% of all lung cancer cases remain without cyto-histological characterisation. The aim of our study was to evaluate retrospectively the proportion of histological and/or cytological diagnosis in patients with lung cancer in Sardinia. Methods. Data was gathered by consulting the hospital registers and case notes of individual patients released from hospital with a diagnosis of Lung Cancer at all medical centres throughout Sardinia. In gathering patients’ data, we focused our attention on cytological and histological procedures through which allowed the lung cancer was diagnosed. Cancer Registries data was utilised to compare our data with national and Sassari province data. Results. From 1991 to 1996 there was a total of 3146 lung cancer patients registered in Sardinia. 1902 patients (60.5%) had a histological diagnosis, 142 patients (4.5%) a cytological diagnosis while in 1102 patients (35%) the diagnosis was performed without any pathological validation. Conclusions. Our study has shown that lung cancer diagnosis is supported by pathological verification in 65% of cases while in remaining 35% of patients the diagnosis is based only on clinical and radiological reports. In Italy data from Cancer Registries report the percentage of cyto- histological diagnosis to be 70% with the percentage of cytological diagnosis being higher than in Sardinia.

scholarly journals Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors

2021 ◽  
Author(s):  
Da Hyun Kang ◽  
Chaeuk Chung ◽  
Pureum Sun ◽  
Da Hye Lee ◽  
Song-I Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Advanced Nsclc ◽  
Checkpoint Inhibitors ◽  
Standard Of Care ◽  
Treg Cells ◽  
University Hospital ◽  
X Rays ◽  
Lung Cancer Patients ◽  
National University

Abstract Background Immune checkpoint inhibitors (ICIs) have become the standard of care for a variety of cancers, including non-small cell lung cancer (NSCLC). In this study, we investigated the frequency of pseudoprogression and hyperprogression in lung cancer patients treated with ICIs in the real world and aimed to discover a novel candidate marker to distinguish pseudoprogression from hyperprogression soon after ICI treatment. Methods This study included 74 patients with advanced NSCLC who were treated with PD-1/PD-L1 inhibitors at Chungnam National University Hospital (CNUH) between January 2018 and August 2020. Chest X-rays were examined on day 7 after the first ICI dose to identify changes in the primary mass, and the response was assessed by computed tomography (CT). We evaluated circulating regulatory T (Treg) cells using flow cytometry and correlated the findings with clinical outcomes. Results The incidence of pseudoprogression was 13.5%, and that of hyperprogression was 8.1%. On day 7 after initiation of treatment, the frequency of CD4+CD25+CD127loFoxP3+ Treg cells was significantly decreased compared with baseline (P = 0.038) in patients who experienced pseudoprogression and significantly increased compared with baseline (P = 0.024) in patients who experienced hyperprogression. In the responder group, the frequencies of CD4+CD25+CD127loFoxP3+ Treg cells and PD-1+CD4+CD25+CD127loFoxP3+ Treg cells were significantly decreased 7 days after commencement of treatment compared with baseline (P = 0.034 and P < 0.001, respectively). Conclusion Circulating Treg cells represent a promising potential dynamic biomarker to predict efficacy and differentiate atypical responses, including pseudoprogression and hyperprogression, after immunotherapy in patients with NSCLC.

scholarly journals P1.03-010 Characteristics of Lung Cancer Patients Diagnosed Following Emergency Admission

2017 ◽  
Vol 12 (1) ◽  
pp. S548
Author(s):  
Mamta Ruparel ◽  
Ayesha Ejaz ◽  
Neil Chauhan ◽  
Melanie Ridge ◽  
Donna Chung ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Emergency Admission ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document